Floatz logo

Clostridium Butyricum Miyairi 588

Nonpapillary Renal Cell Carcinoma

City of Hope Medical Centerother_biologicalPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

111 Active assets in the Nonpapillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
Pazopanib
Academic and Community Cancer Research United
Phase 4BB
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Regeneron Pharmaceuticals
Phase 2BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Cabozantinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Clostridium Butyricum Miyairi 588 is also rated in:

renal cell carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
sarcomatoid renal cell carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
papillary renal cell carcinomaActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →